BUSM’s Benjamin Wolozin to Serve on NIH Study Section

Benjamin Wolozin, MD, PhD, a BUSM professor of pharmacology and neurology, has accepted an invitation to serve as a member of the Cellular and Molecular Biology of Neurodegeneration (CMND) Study Section for the National Institutes of Health (NIH). Wolozin’s term will begin July 1 and continue until June 30, 2013.

The NIH selects members to serve on the CMND study section based on their demonstrated competence and achievement in a scientific discipline as evidenced by scientific activities, achievements and honors including quality research findings and publications in journals. The selection provides members with a unique opportunity to contribute to the national biomedical research effort by reviewing grant applications, making recommendations based on them and surveying the status of research in their fields of science.

“Participating on study sections is an important element of being a ‘citizen’ of the scientific community,” said Wolozin. “I have participated on study sections since I became a professor in the 1990s. My current appointment to the CMND study section represents a continuation of this process, and reflects my deep commitment to the scientific community.”

Wolozin joined BUSM’s Department of Pharmacology in 2004 and now holds an adjunct position in the Department of Neurology. His primary research interests focus on the pathophysiology of Alzheimer’s and Parkinson’s disease. He currently serves as the primary investigator for several funded studies and has received numerous awards for his research including the Donald B. Lindsley Prize from the Society of Neuroscience and the A. E. Bennett Award from the Society for Biological Psychiatry.